A fully Bayesian approach for sample size determination for a clinical trial is presented in which the final decision whether to use the new treatment is taken by potential users and their medical advisers on the basis of the strength of the evidence provided by the trial. Data are assumed to come from two independent binomial distributions and the parameter of interest is , where and are two independent proportions. The optimal size is obtained by maximizing the expected net benefit function, which is the expected benefit from subsequent use of the new treatment minus the cost of the tria
', './data/iijs/coversheet/cover_en.jpg'))